Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis's Farydak Enters EU As First-In-Class Myeloma Therapy

This article was originally published in Scrip

Executive Summary

Novartis AG's histone deacetylase (HDAC) inhibitor Farydak (panobinostat; also known as Faridak) has secured approval in Europe for the treatment of multiple myeloma – making it the first drug of this class to reach the European market.



Related Companies